The document discusses surgical haemostasis, which is the process of preventing or stopping blood loss from injured blood vessels during or after surgery. It defines haemostasis and outlines its importance in surgery. The physiology of haemostasis is described, involving vasoconstriction, platelet plug formation, and coagulation/fibrin formation. Causes of bleeding during or after surgery are discussed, including defects in haemostasis or platelet function. Methods of achieving haemostasis are covered, such as mechanical techniques like pressure, sutures, and cauterization, as well as chemical agents, blood products, and thermal techniques. Management of haemostasis in the pre-operative, intra-operative, and post-operative periods
This document summarizes blood coagulation and hemostasis. It discusses platelets, the platelet plug formation process, and the intrinsic and extrinsic pathways of blood coagulation. Disorders of coagulation covered include hemophilia A/B/C, von Willebrand disease, and purpura. Tests of hemostatic function like bleeding time, clotting time, and prothrombin time are also outlined. Anticoagulants like heparin and warfarin are briefly described.
[Int. med] bleeding disorders from SIMS LahoreMuhammad Ahmad
This document discusses bleeding and clotting disorders. It provides details on:
1. The normal physiology of hemostasis including vascular, platelet and plasma factors that prevent bleeding.
2. Specific platelet and plasma factor deficiencies that can cause bleeding disorders.
3. The classification of bleeding disorders into defects of blood vessels, platelet disorders, and clotting factor deficiencies.
4. Diagnostic tests for evaluating bleeding patients including screening coagulation tests, specific factor assays, and platelet function tests.
Hemostasis and coagulation of blood by Pandian M, Tutor, Dept of Physiology, ...Pandian M
DEFINITION Hemostasis
STAGES OF HEMOSTASIS
VASOCONSTRICTION
PLATELET PLUG FORMATION
COAGULATION OF BLOOD DEFINITION
FACTORS INVOLVED IN BLOOD CLOTTING
SEQUENCE OF CLOTTING MECHANISM
BLOOD CLOT
ANTICLOTTING MECHANISM IN THE BODY
ANTICOAGULANTS
PHYSICAL METHODS TO PREVENT BLOOD CLOTTING
PROCOAGULANTS
TESTS FOR BLOOD CLOTTING
APPLIED PHYSIOLOGY
This document provides information on platelets, hemostasis, coagulation of blood, and related topics. It describes the components and functions of platelets, including their granules that contain factors involved in coagulation. The stages of hemostasis and coagulation are outlined, including vasoconstriction, formation of the platelet plug, development of a fibrin clot, and clot retraction. Coagulation factors, the enzyme cascade theory of coagulation, and natural anticoagulation mechanisms are also summarized. Bleeding disorders like hemophilia, purpura, and von Willebrand disease are briefly described.
This document provides an overview of haemostasis and coagulation. It defines haemostasis as the arrest of bleeding and describes the two stages as primary haemostasis involving platelet plug formation and secondary haemostasis involving fibrin clot formation via the coagulation cascade. Key aspects of both the intrinsic and extrinsic pathways are summarized. Common coagulation factor deficiencies and disorders are also mentioned.
This document provides an overview of haemostasis (hemostasis). It consists of five main sections:
1. Components of haemostasis - the vascular system, platelets, coagulation, fibrinolysis, and coagulation inhibition systems.
2. The haemostatic process - consisting of vasoconstriction, platelet plug formation, coagulation cascade, and fibrin clot formation and dissolution.
3. Haemostatic disorders - bleeding disorders due to problems with vessels, platelets, or coagulation factors, and thrombotic disorders.
4. Specific coagulation factor deficiencies - von Willebrand disease, hemophilia A/B, liver disease, vitamin K deficiency.
5
This document summarizes blood coagulation and hemostasis. It discusses platelets, the platelet plug formation process, and the intrinsic and extrinsic pathways of blood coagulation. Disorders of coagulation covered include hemophilia A/B/C, von Willebrand disease, and purpura. Tests of hemostatic function like bleeding time, clotting time, and prothrombin time are also outlined. Anticoagulants like heparin and warfarin are briefly described.
[Int. med] bleeding disorders from SIMS LahoreMuhammad Ahmad
This document discusses bleeding and clotting disorders. It provides details on:
1. The normal physiology of hemostasis including vascular, platelet and plasma factors that prevent bleeding.
2. Specific platelet and plasma factor deficiencies that can cause bleeding disorders.
3. The classification of bleeding disorders into defects of blood vessels, platelet disorders, and clotting factor deficiencies.
4. Diagnostic tests for evaluating bleeding patients including screening coagulation tests, specific factor assays, and platelet function tests.
Hemostasis and coagulation of blood by Pandian M, Tutor, Dept of Physiology, ...Pandian M
DEFINITION Hemostasis
STAGES OF HEMOSTASIS
VASOCONSTRICTION
PLATELET PLUG FORMATION
COAGULATION OF BLOOD DEFINITION
FACTORS INVOLVED IN BLOOD CLOTTING
SEQUENCE OF CLOTTING MECHANISM
BLOOD CLOT
ANTICLOTTING MECHANISM IN THE BODY
ANTICOAGULANTS
PHYSICAL METHODS TO PREVENT BLOOD CLOTTING
PROCOAGULANTS
TESTS FOR BLOOD CLOTTING
APPLIED PHYSIOLOGY
This document provides information on platelets, hemostasis, coagulation of blood, and related topics. It describes the components and functions of platelets, including their granules that contain factors involved in coagulation. The stages of hemostasis and coagulation are outlined, including vasoconstriction, formation of the platelet plug, development of a fibrin clot, and clot retraction. Coagulation factors, the enzyme cascade theory of coagulation, and natural anticoagulation mechanisms are also summarized. Bleeding disorders like hemophilia, purpura, and von Willebrand disease are briefly described.
This document provides an overview of haemostasis and coagulation. It defines haemostasis as the arrest of bleeding and describes the two stages as primary haemostasis involving platelet plug formation and secondary haemostasis involving fibrin clot formation via the coagulation cascade. Key aspects of both the intrinsic and extrinsic pathways are summarized. Common coagulation factor deficiencies and disorders are also mentioned.
This document provides an overview of haemostasis (hemostasis). It consists of five main sections:
1. Components of haemostasis - the vascular system, platelets, coagulation, fibrinolysis, and coagulation inhibition systems.
2. The haemostatic process - consisting of vasoconstriction, platelet plug formation, coagulation cascade, and fibrin clot formation and dissolution.
3. Haemostatic disorders - bleeding disorders due to problems with vessels, platelets, or coagulation factors, and thrombotic disorders.
4. Specific coagulation factor deficiencies - von Willebrand disease, hemophilia A/B, liver disease, vitamin K deficiency.
5
The presentation deals with the basics of hemorrhage i.e. classification, etiology. It also covers the mechanism of hemostasis and the various methods to achieve hemostasis.
Hope you like it! Suggestions and feedback will always be well appreciated. :)
Hemostasis is the process of blood clotting and subsequent dissolution of the clot following tissue repair. It involves 3 main events: 1) vascular constriction, 2) platelet aggregation forming a temporary plug, and 3) fibrin formation creating a stable clot. The clot must later dissolve for normal blood flow to resume. Von Willebrand disease is a bleeding disorder caused by deficient or abnormal von Willebrand factor, which helps platelets bind to collagen. It ranges from mild to severe and is diagnosed based on bleeding history and lab tests of von Willebrand factor and coagulation factors. Treatment depends on severity but may include desmopressin or coagulation factor replacement.
This document discusses surgical hemostasis. It begins by outlining the learning objectives, which are to understand what hemostasis is, the causes of excessive bleeding during or after surgery, and how to evaluate a patient's hemostasis before surgery. It then defines hemostasis as the arrest of blood escape through natural or artificial means. It describes the natural hemostasis process involving vasoconstriction, platelet plug formation, and blood clot formation. It lists the 12 clotting factors and the intrinsic and extrinsic clotting pathways. The document concludes by discussing causes of bleeding during or after surgery, including defects of hemostasis, and the steps of pre-operative evaluation of a patient's hemost
This document discusses disseminated intravascular coagulation (DIC), including:
1. It defines DIC as a condition where blood clots form throughout the small blood vessels, reducing blood flow and damaging organs. It involves activation of both clotting and fibrinolytic systems due to widespread endothelial damage.
2. Risk factors for DIC include sepsis, trauma, obstetric complications like abruptio placentae, malignancy, and liver or renal failure. Complications can include organ dysfunction, thrombosis, and life-threatening hemorrhage.
3. Investigations show decreased platelet count, fibrinogen, and increased PT, PTT, D-dimer. Peripheral smear shows sch
This document provides an overview of hemostasis, the process by which bleeding is stopped. It discusses the key mechanisms of hemostasis, including:
1) Vascular constriction which reduces blood flow to the injury site.
2) Formation of a platelet plug via platelet adhesion, granule release and aggregation.
3) Formation of a blood clot through the coagulation cascade which involves the intrinsic, extrinsic, and common pathways leading to thrombin generation and fibrin clot formation.
Investigation of hemostatic function includes tests of vascular hemostasis, platelet function, and coagulation factor assays to identify abnormalities that may cause bleeding disorders.
This document provides an overview of haemostasis (hemostasis). It begins by defining haemostasis as the physiological process involving cells, soluble factors, and proteins that maintains blood in a fluid state and arrests bleeding after trauma. It then describes the two types of haemostasis - primary (formation of platelet plug) and secondary (coagulation protein-mediated). The document outlines the process of haemostasis including vasoconstriction, platelet plug formation, activation of coagulation, and plug dissolution. It also discusses coagulation factors, laboratory tests, haemostatic agents, and bleeding disorders.
Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...Pandian M
Blood coagulation
Mechanism of coagulation
STAGES OF HEMOSTASIS
Coagulation of blood
Factors involved in blood clotting
Enzyme cascade theory
Mechanisms for formation of prothrombin activator
Fibrinolysis
Anticlotting mechanism in the body
Applied physiology
This document provides information about idiopathic thrombocytopenic purpura (ITP) during pregnancy, including its pathophysiology, clinical presentation, diagnostic testing, treatment options, and complications. ITP is caused by maternal antibodies destroying platelets, which can lead to fetal thrombocytopenia through placental transfer of antibodies. Treatment aims to maintain maternal platelet counts above 20,000/mm3 antepartum and 50,000/mm3 for delivery to prevent bleeding. First-line treatments include corticosteroids, intravenous immunoglobulin, and platelet transfusions.
This document discusses coagulopathy, which refers to medical disorders involving abnormal blood clotting due to deficiencies or issues with platelets, clotting factors, or the fibrinolytic system. It defines various bleeding disorders and coagulation tests. Specific conditions covered include immune thrombocytopenic purpura (ITP), von Willebrand disease, hemophilia A/B, and disseminated intravascular coagulation (DIC). Treatment involves replacing the deficient clotting factor, managing underlying causes, or administering medications depending on the condition causing the coagulopathy. Complications can include excessive bleeding, joint damage, and transmission of infections.
The document discusses various aspects of hemostasis including:
1. Hemostasis involves biological processes that stop bleeding through vascular wall integrity, maintaining blood fluidity, and forming clots at sites of injury.
2. Abnormalities of hemostasis include hemorrhagic diathesis, thrombosis, and disseminated intravascular coagulation (DIC).
3. Hemorrhagic diathesis has causes related to vascular disorders, thrombocytopenia, thrombocytopathy, and coagulopathy.
1. Venous pathophysiology involves a complex interplay between genetic, environmental, and acquired factors that can disrupt the normal balance between procoagulant and anticoagulant mechanisms in the veins.
2. The venous endothelium plays a critical role in homeostasis by maintaining an anticoagulant state, but this can be damaged by various disease processes, promoting thrombosis.
3. Abnormal venous biomechanics and valve incompetence, as seen in varicose veins and post-thrombotic syndrome, can lead to ambulatory venous hypertension from impaired flow and reflux of blood in the veins.
This seminar includes hemostasis,mechanism of blood clotting and associated blood dyscrasias commonly seen in children and their treatments with a note on antifibrinolytics
Hemostasis
Seminar Prepared by :-
Mohammed Saadi
Mohammed Musa
Hussein Jassam
Mahmoud Ahmed
Internal Medicine
College of Medicine - University of Kirkuk
Hemostasis is the process of stopping bleeding through formation of a blood clot. It involves platelets, coagulation factors, and endothelium. There are two stages: primary hemostasis forms a weak platelet plug, and secondary hemostasis stabilizes it via the coagulation cascade. Disorders can cause bleeding or thrombosis. Primary disorders involve platelets and cause bleeding from mucosa or skin. Secondary disorders involve coagulation factors and cause deep tissue or postoperative bleeding. Thrombosis occurs when clots form inside blood vessels due to disrupted blood flow, endothelial cell damage, or a hypercoagulable state. Emboli are detached clots or particles that travel through the bloodstream and can cause pulmonary
Bleeding disorders result from problems with blood clotting and can range from mild to life-threatening. The coagulation cascade describes the series of biochemical reactions involved in clotting. There are two pathways - intrinsic and extrinsic - that activate clotting factors and ultimately form a fibrin clot. Common symptoms include bruising, nosebleeds, and heavy periods. Investigations may include blood tests of clotting factors and bleeding time. Specific deficiencies are diagnosed through factor assays and gene analysis. Treatment depends on the underlying condition.
PC of Blood and Blood forming agents.pdfRAMDAS BHAT
This document provides an overview of drugs acting on blood and blood forming agents. It discusses coagulants that promote coagulation like calcium salts and vitamin K. It also discusses anticoagulants that prevent coagulation, including heparin, low molecular weight heparins, direct thrombin inhibitors, factor Xa inhibitors, and vitamin K antagonists like warfarin. The document provides details on the mechanisms of coagulation, platelet function, fibrinolysis, and conditions requiring treatment with coagulants or anticoagulants.
COAGULATION FACTORS AND DENTAL PROCEDURES NarmathaN2
Coagulation factors are proteins in the blood that work together to help form blood clots. Some coagulation factor deficiencies can cause bleeding disorders like hemophilia. For dental procedures in patients with coagulation issues, replacement of deficient factors or use of antifibrinolytic drugs is often needed before, during, and after treatment to reduce bleeding risks. Local anesthetic techniques that minimize trauma are preferred. Proper factor level monitoring and hemostatic support tailored to the specific condition can allow for many routine dental treatments to be completed safely.
The document summarizes key aspects of haemostasis including the vascular, platelet and clotting phases. It describes tests used to diagnose bleeding disorders affecting primary (platelets) and secondary (clotting factors) hemostasis. Clinical features of platelet and coagulation disorders are compared. The implications of bleeding disorders for periodontal treatment are discussed, highlighting the need to modify procedures and use hemostatic measures depending on the nature and severity of the underlying condition.
The document discusses the coagulation cascade and cell-based model of hemostasis. It describes the intrinsic and extrinsic pathways that activate thrombin and fibrinogen to form a clot. Congenital disorders like hemophilia A and B and von Willebrand disease are discussed. Acquired bleeding disorders from liver disease, vitamin deficiencies, DIC and autoimmune conditions are also summarized. The document outlines tests for screening coagulation factors and platelets and diagnosing specific bleeding disorders.
This document discusses the pathology and management of malignant bowel obstruction. It defines malignant bowel obstruction as luminal narrowing of the small or large bowel due to metastatic cancer. The most common primary cancers causing MBO are colorectal, ovarian, stomach, and pancreatic cancers. The document outlines the classification, signs and symptoms, diagnostic tests including CT scan, and various treatment options for MBO, including surgical resection, endoscopic stenting, non-operative management with medications like octreotide to relieve symptoms, and palliative care since MBO represents terminal cancer. The primary goals of treatment are palliation to improve quality of life by relieving nausea, vomiting and pain.
- Malignant melanoma is a deadly form of skin cancer that has been increasing in incidence over the past 50 years.
- It typically presents as an asymmetric mole with irregular borders and varies in color.
- Risk factors include family history, numerous moles, sun exposure, and fair skin.
- Staging involves evaluating tumor thickness and spread. Treatment may include surgery, lymph node assessment, radiation, immunotherapy, and targeted drug therapy. Prognosis depends on stage, with thinner tumors having better survival rates.
The presentation deals with the basics of hemorrhage i.e. classification, etiology. It also covers the mechanism of hemostasis and the various methods to achieve hemostasis.
Hope you like it! Suggestions and feedback will always be well appreciated. :)
Hemostasis is the process of blood clotting and subsequent dissolution of the clot following tissue repair. It involves 3 main events: 1) vascular constriction, 2) platelet aggregation forming a temporary plug, and 3) fibrin formation creating a stable clot. The clot must later dissolve for normal blood flow to resume. Von Willebrand disease is a bleeding disorder caused by deficient or abnormal von Willebrand factor, which helps platelets bind to collagen. It ranges from mild to severe and is diagnosed based on bleeding history and lab tests of von Willebrand factor and coagulation factors. Treatment depends on severity but may include desmopressin or coagulation factor replacement.
This document discusses surgical hemostasis. It begins by outlining the learning objectives, which are to understand what hemostasis is, the causes of excessive bleeding during or after surgery, and how to evaluate a patient's hemostasis before surgery. It then defines hemostasis as the arrest of blood escape through natural or artificial means. It describes the natural hemostasis process involving vasoconstriction, platelet plug formation, and blood clot formation. It lists the 12 clotting factors and the intrinsic and extrinsic clotting pathways. The document concludes by discussing causes of bleeding during or after surgery, including defects of hemostasis, and the steps of pre-operative evaluation of a patient's hemost
This document discusses disseminated intravascular coagulation (DIC), including:
1. It defines DIC as a condition where blood clots form throughout the small blood vessels, reducing blood flow and damaging organs. It involves activation of both clotting and fibrinolytic systems due to widespread endothelial damage.
2. Risk factors for DIC include sepsis, trauma, obstetric complications like abruptio placentae, malignancy, and liver or renal failure. Complications can include organ dysfunction, thrombosis, and life-threatening hemorrhage.
3. Investigations show decreased platelet count, fibrinogen, and increased PT, PTT, D-dimer. Peripheral smear shows sch
This document provides an overview of hemostasis, the process by which bleeding is stopped. It discusses the key mechanisms of hemostasis, including:
1) Vascular constriction which reduces blood flow to the injury site.
2) Formation of a platelet plug via platelet adhesion, granule release and aggregation.
3) Formation of a blood clot through the coagulation cascade which involves the intrinsic, extrinsic, and common pathways leading to thrombin generation and fibrin clot formation.
Investigation of hemostatic function includes tests of vascular hemostasis, platelet function, and coagulation factor assays to identify abnormalities that may cause bleeding disorders.
This document provides an overview of haemostasis (hemostasis). It begins by defining haemostasis as the physiological process involving cells, soluble factors, and proteins that maintains blood in a fluid state and arrests bleeding after trauma. It then describes the two types of haemostasis - primary (formation of platelet plug) and secondary (coagulation protein-mediated). The document outlines the process of haemostasis including vasoconstriction, platelet plug formation, activation of coagulation, and plug dissolution. It also discusses coagulation factors, laboratory tests, haemostatic agents, and bleeding disorders.
Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...Pandian M
Blood coagulation
Mechanism of coagulation
STAGES OF HEMOSTASIS
Coagulation of blood
Factors involved in blood clotting
Enzyme cascade theory
Mechanisms for formation of prothrombin activator
Fibrinolysis
Anticlotting mechanism in the body
Applied physiology
This document provides information about idiopathic thrombocytopenic purpura (ITP) during pregnancy, including its pathophysiology, clinical presentation, diagnostic testing, treatment options, and complications. ITP is caused by maternal antibodies destroying platelets, which can lead to fetal thrombocytopenia through placental transfer of antibodies. Treatment aims to maintain maternal platelet counts above 20,000/mm3 antepartum and 50,000/mm3 for delivery to prevent bleeding. First-line treatments include corticosteroids, intravenous immunoglobulin, and platelet transfusions.
This document discusses coagulopathy, which refers to medical disorders involving abnormal blood clotting due to deficiencies or issues with platelets, clotting factors, or the fibrinolytic system. It defines various bleeding disorders and coagulation tests. Specific conditions covered include immune thrombocytopenic purpura (ITP), von Willebrand disease, hemophilia A/B, and disseminated intravascular coagulation (DIC). Treatment involves replacing the deficient clotting factor, managing underlying causes, or administering medications depending on the condition causing the coagulopathy. Complications can include excessive bleeding, joint damage, and transmission of infections.
The document discusses various aspects of hemostasis including:
1. Hemostasis involves biological processes that stop bleeding through vascular wall integrity, maintaining blood fluidity, and forming clots at sites of injury.
2. Abnormalities of hemostasis include hemorrhagic diathesis, thrombosis, and disseminated intravascular coagulation (DIC).
3. Hemorrhagic diathesis has causes related to vascular disorders, thrombocytopenia, thrombocytopathy, and coagulopathy.
1. Venous pathophysiology involves a complex interplay between genetic, environmental, and acquired factors that can disrupt the normal balance between procoagulant and anticoagulant mechanisms in the veins.
2. The venous endothelium plays a critical role in homeostasis by maintaining an anticoagulant state, but this can be damaged by various disease processes, promoting thrombosis.
3. Abnormal venous biomechanics and valve incompetence, as seen in varicose veins and post-thrombotic syndrome, can lead to ambulatory venous hypertension from impaired flow and reflux of blood in the veins.
This seminar includes hemostasis,mechanism of blood clotting and associated blood dyscrasias commonly seen in children and their treatments with a note on antifibrinolytics
Hemostasis
Seminar Prepared by :-
Mohammed Saadi
Mohammed Musa
Hussein Jassam
Mahmoud Ahmed
Internal Medicine
College of Medicine - University of Kirkuk
Hemostasis is the process of stopping bleeding through formation of a blood clot. It involves platelets, coagulation factors, and endothelium. There are two stages: primary hemostasis forms a weak platelet plug, and secondary hemostasis stabilizes it via the coagulation cascade. Disorders can cause bleeding or thrombosis. Primary disorders involve platelets and cause bleeding from mucosa or skin. Secondary disorders involve coagulation factors and cause deep tissue or postoperative bleeding. Thrombosis occurs when clots form inside blood vessels due to disrupted blood flow, endothelial cell damage, or a hypercoagulable state. Emboli are detached clots or particles that travel through the bloodstream and can cause pulmonary
Bleeding disorders result from problems with blood clotting and can range from mild to life-threatening. The coagulation cascade describes the series of biochemical reactions involved in clotting. There are two pathways - intrinsic and extrinsic - that activate clotting factors and ultimately form a fibrin clot. Common symptoms include bruising, nosebleeds, and heavy periods. Investigations may include blood tests of clotting factors and bleeding time. Specific deficiencies are diagnosed through factor assays and gene analysis. Treatment depends on the underlying condition.
PC of Blood and Blood forming agents.pdfRAMDAS BHAT
This document provides an overview of drugs acting on blood and blood forming agents. It discusses coagulants that promote coagulation like calcium salts and vitamin K. It also discusses anticoagulants that prevent coagulation, including heparin, low molecular weight heparins, direct thrombin inhibitors, factor Xa inhibitors, and vitamin K antagonists like warfarin. The document provides details on the mechanisms of coagulation, platelet function, fibrinolysis, and conditions requiring treatment with coagulants or anticoagulants.
COAGULATION FACTORS AND DENTAL PROCEDURES NarmathaN2
Coagulation factors are proteins in the blood that work together to help form blood clots. Some coagulation factor deficiencies can cause bleeding disorders like hemophilia. For dental procedures in patients with coagulation issues, replacement of deficient factors or use of antifibrinolytic drugs is often needed before, during, and after treatment to reduce bleeding risks. Local anesthetic techniques that minimize trauma are preferred. Proper factor level monitoring and hemostatic support tailored to the specific condition can allow for many routine dental treatments to be completed safely.
The document summarizes key aspects of haemostasis including the vascular, platelet and clotting phases. It describes tests used to diagnose bleeding disorders affecting primary (platelets) and secondary (clotting factors) hemostasis. Clinical features of platelet and coagulation disorders are compared. The implications of bleeding disorders for periodontal treatment are discussed, highlighting the need to modify procedures and use hemostatic measures depending on the nature and severity of the underlying condition.
The document discusses the coagulation cascade and cell-based model of hemostasis. It describes the intrinsic and extrinsic pathways that activate thrombin and fibrinogen to form a clot. Congenital disorders like hemophilia A and B and von Willebrand disease are discussed. Acquired bleeding disorders from liver disease, vitamin deficiencies, DIC and autoimmune conditions are also summarized. The document outlines tests for screening coagulation factors and platelets and diagnosing specific bleeding disorders.
This document discusses the pathology and management of malignant bowel obstruction. It defines malignant bowel obstruction as luminal narrowing of the small or large bowel due to metastatic cancer. The most common primary cancers causing MBO are colorectal, ovarian, stomach, and pancreatic cancers. The document outlines the classification, signs and symptoms, diagnostic tests including CT scan, and various treatment options for MBO, including surgical resection, endoscopic stenting, non-operative management with medications like octreotide to relieve symptoms, and palliative care since MBO represents terminal cancer. The primary goals of treatment are palliation to improve quality of life by relieving nausea, vomiting and pain.
- Malignant melanoma is a deadly form of skin cancer that has been increasing in incidence over the past 50 years.
- It typically presents as an asymmetric mole with irregular borders and varies in color.
- Risk factors include family history, numerous moles, sun exposure, and fair skin.
- Staging involves evaluating tumor thickness and spread. Treatment may include surgery, lymph node assessment, radiation, immunotherapy, and targeted drug therapy. Prognosis depends on stage, with thinner tumors having better survival rates.
This document provides an overview of principles of management of burns. It defines burns and discusses epidemiology, anatomy of the skin, pathology and pathophysiology of burns. It also covers classification of burns by depth and extent, management including fluid resuscitation, wound dressings, surgery, pain management and infection control. Specific management of electrical burns is also discussed.
Antibiotics are antimicrobial substances that are used to treat and prevent infections in surgery. There are several principles for the appropriate use of antibiotics including selecting antibiotics based on the likely pathogen, using the narrowest spectrum antibiotic when possible, and administering antibiotics at the proper dose and duration. Antibiotics can be used prophylactically before surgery to prevent infection or therapeutically to treat an established infection, and the choice is guided by clinical diagnosis, culture results when available, and the urgency of the situation. Indiscriminate antibiotic use can promote resistance and should be avoided.
This document provides an overview of principles of cancer chemotherapy. It defines key terms and outlines the goals of chemotherapy as curative or palliative. The cell cycle is described and how different classes of chemotherapeutic agents work at specific phases. Principles of chemotherapy administration include pre-assessment, counseling, modality selection, dose optimization, administration procedures, management of side effects and follow up. Common drug classes and regimens are mentioned along with mechanisms of drug resistance and future trends in chemotherapy.
PRINCIPLES OF ORGAN TRANSPLANTATION 2003.pptOlofin Kayode
The document provides an overview of principles of transplant surgery. It defines different types of transplants including autotransplants, allotransplants, and xenotransplants. It discusses the history of transplantation, basic immunology including HLA antigens and allo-graft rejection. It also covers clinical immunosuppression with drugs like corticosteroids and cyclosporin. Organ procurement, specific organ transplants, and future trends are briefly mentioned.
Principle of Organ Transplantation.pptxOlofin Kayode
The document provides an overview of organ transplantation, including:
- Definitions of different types of organ transplants such as allografts and xenografts.
- A historical background of major transplant milestones from the 1950s onward including the first successful kidney, liver, lung, and heart transplants.
- Details about transplant immunology, the immune response to foreign organs, and ways to suppress the immune system like with immunosuppressant drugs.
- The types of organ rejection such as hyperacute, acute, and chronic rejection.
- Considerations for organ donation, procurement, preservation, and transplantation.
- Complications after transplantation like infection and potential future directions.
Principles of cancer chemotherapy(1).pptxOlofin Kayode
This document provides an overview of principles of cancer chemotherapy. It defines key terms and outlines the goals of chemotherapy as curative or palliative. The cell cycle is described and how different classes of chemotherapeutic agents work at specific phases. Principles of chemotherapy administration include pre-assessment, counseling, modality selection, dose optimization, administration procedures, management of side effects and follow up. Common drug classes and regimens are mentioned along with mechanisms of drug resistance and future trends in chemotherapy.
This document provides an overview of surgical site infections (SSIs). It defines SSIs and related terms like colonization and contamination. It discusses the historical context, epidemiology, classification, pathogenesis, clinical features, and factors that influence SSIs. The document also covers prevention strategies like proper patient preparation, aseptic technique, and antibiotic prophylaxis. It describes approaches for clinical assessment, wound scoring systems, and management of SSIs.
This document outlines the process and importance of preanesthetic evaluation. It defines preanesthetic evaluation as a medical check-up and lab tests done before surgery to assess patient health and risks. The evaluation aims to optimize patient preparation, ensure surgery is realistic, and anticipate problems. It involves taking a medical history, examining the patient, ordering relevant tests, and developing a preoperative plan. Factors like ASA grade and POSSUM score can help predict perioperative risks. The evaluation helps educate patients, organize care, and plan anesthesia to improve surgical outcomes.
This document discusses the anatomy, classification, clinical features, investigations, and treatment techniques for peripheral nerve injuries. Some key points include:
- Peripheral nerves are composed of bundles of axons surrounded by connective tissue sheaths including the epineurium, perineurium, and endoneurium.
- Nerve injuries are classified based on the severity of damage, with neuropraxia having the best prognosis and neurotmesis having the worst.
- Treatment depends on the type and severity of injury, and may include non-operative management, primary repair, nerve grafting, nerve transfers, or the use of conduits.
- Prognosis is best when the injury
The document discusses the metabolic response to trauma, which refers to adaptive changes that maintain homeostasis after injury. It outlines the triggers, components, and sequelae of the metabolic response. The components include sympathetic nervous system activation, endocrine responses like increased cortisol and growth hormone, and cytokine responses from interleukins and tumor necrosis factor. Prolonged or accentuated metabolic responses can harm surgical patients by increasing energy needs, reducing immunity, and impairing wound healing. The response can be attenuated by measures like fluid replacement, analgesia, nutritional support, and prompt infection treatment.
This document provides an overview of sepsis and septic shock, including definitions, epidemiology, pathogenesis, clinical features, investigation, treatment, complications, and prognosis. It defines sepsis as infection plus SIRS, and septic shock as sepsis that is not responsive to fluid resuscitation and requires vasopressors. The pathogenesis involves an initial inflammatory response to infection that can become dysregulated and lead to organ dysfunction. Treatment involves prompt resuscitation, antibiotics, source control, and organ support. Outcomes depend on factors like age, immune status, pathogen, and need for prolonged vasopressor support.
Day case surgery, also known as ambulatory surgery, involves planned admission and discharge of a patient within 12 hours for a surgical procedure. It provides several benefits over traditional inpatient surgery such as shorter hospital stays, lower infection rates, and more efficient use of healthcare resources. Common procedures performed as day cases include hernia repairs, cataract removal, and tonsillectomies. Careful patient selection and optimization, as well as coordinated perioperative management involving preoperative assessment and education, regional anesthesia when possible, early mobilization and feeding, and established discharge criteria are important for success. Day case surgery allows for treatment of more patients while maintaining high quality care.
This document provides an overview of deep vein thrombosis (DVT) and pulmonary embolism (PE). It covers the definition, epidemiology, risk factors, clinical features, investigations, management including prevention, treatment and anticoagulation. DVT occurs when a blood clot forms in a deep vein, usually in the legs, while PE is a complication that can occur when part of the clot breaks off and travels to the lungs. The document outlines Virchow's triad of factors that contribute to clot formation and discusses various diagnostic tests and therapeutic approaches for DVT and PE.
Fluid and Electrolyte Management in Surgery.pptOlofin Kayode
This document provides an outline and introduction to fluid and electrolyte management in surgery. It discusses the normal distribution and balance of body water and electrolytes like sodium, potassium, calcium and magnesium. It describes various fluid and electrolyte disorders that can occur including volume disturbances, concentration disturbances and composition disturbances. It covers causes, clinical features and treatment of conditions like hyponatremia, hypernatremia, hypokalemia, hyperkalemia, hypocalcemia, hypercalcemia and acid-base imbalances. The document emphasizes the importance of fluid and electrolyte management in the perioperative care of surgical patients.
This document discusses pain from multiple perspectives:
- It defines pain and provides a brief history of pain theories.
- Pain is classified and the physiology of pain transmission is explained through multiple stages from nociception to perception.
- Different types of pain like acute, chronic, neuropathic, and referred pain are described.
- Pain assessment and various scales used to evaluate pain are outlined.
- Non-pharmacological and pharmacological management of pain are summarized.
The document discusses nutrition in surgery, outlining relevant physiology, basic nutrient requirements, causes of malnutrition, nutritional assessment techniques, energy requirements, indications for nutritional support, and methods of enteral and parenteral nutrition to correct deficiencies and support patients during and after surgery. Nutritional support can help reduce complications from malnutrition like impaired wound healing and increased risk of infection.
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Muktapishti is a traditional Ayurvedic preparation made from Shoditha Mukta (Purified Pearl), is believed to help regulate thyroid function and reduce symptoms of hyperthyroidism due to its cooling and balancing properties. Clinical evidence on its efficacy remains limited, necessitating further research to validate its therapeutic benefits.
Cell Therapy Expansion and Challenges in Autoimmune DiseaseHealth Advances
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
Osteoporosis - Definition , Evaluation and Management .pdfJim Jacob Roy
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Basavarajeeyam is a Sreshta Sangraha grantha (Compiled book ), written by Neelkanta kotturu Basavaraja Virachita. It contains 25 Prakaranas, First 24 Chapters related to Rogas& 25th to Rasadravyas.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
2. OUTLIINE
Introduction
• Definition
• Surgical importance
• Brief history
Physiology of haemostasis
Causes of bleeding during or after surgery
Methods of hemostasis
Management of haemostasis in a surgical patient
• Pre op evaluation
• Intra op management
• Post op management
• Haemostasis in trauma
Conclusion
References
3. INTRODUCTION
Definition
• Hemostasis is the process of forming clots in the walls of damaged
blood vessels and preventing blood loss while maintaining blood in
the fluid state within the vascular system.
4. INTRODUCTION
• The process of preventing or terminating blood loss from an injured
vessel
• Delicate balance between Pro and Anti coagulants
• Congenital and acquired defects result in clinically important
derangements
• Derangements in this process could cause uncontrollable hemorrhage
both spontaneously and on table
• The surgeon has a great role to play
5. INTRODUCTION
Surgical Importance
• Surgical haemostasis is one of the pillars of modern surgery (others
include anesthesia, antibiotics)
• Adequate surgical haemostasis reduces morbidity and mortality in
post. op patients by
– minimizing blood loss and anemia,
– attenuates the metabolic response to trauma,
– reducing infection and
– improving wound healing.
6. INTRODUCTION
Brief History
• The evolution of modern surgery has followed closely behind strides
in surgical hemostasis
• Ancient medicine men and barber surgeons developed maneuvers
based on intuition to control bleeding in their patients
• These intuitions informed scientific research and the elucidation of
the hemostatic process and modern interventions to achieve
hemostasis
7.
8. Physiology Of Haemostasis
Natural inhibitors of coagulation cascade
• Smoothness of the endothelium
• Continuous blood flow
• Prostacyclin (secreted by the platelets)
• Heparin (secreted by the mast cells)
• Antithrombin III (secreted by the liver)
• Protein C & S (natural anticoagulants)
9. Physiology Of Haemostasis cont…
• Involves three (3) interdependent mechanisms
– Initial Vasoconstriction
– Platelet plug formation
– Coagulation/Fibrin formation and Fibrinolysis
• They are interrelated and occur as a continuum.
• Their products provide multiple reinforcements.
10. Physiology Of Haemostasis cont.…
Vaso-constriction
• The initial vascular response to injury.
• Dependent upon local contraction of smooth muscles.
• Occurs before platelet adhesion to site of injury.
• Effectiveness is dependent on type of vessel, calibre, perivascular
pressure, pattern of injury
• Vasoconstrictors: 5-HT, TXA2, bradykinins, fibrinopeptides,
Perivascular pressure
12. Physiology Of Haemostasis cont.…
Platelet Plug Formation
• Platelets become “sticky” when
exposed to sub-endothelial
collagen to which they become
adherent.
• vWF is necessary for Platelet
collagen adherence
• The adherent platelets swell,
initiate a release reaction to
recruit other platelets which
aggregates to form a loose
platelet plug – primary
hemostatic plug
13. Physiology Of Haemostasis cont.…
Primary hemostasis
– Forms loose platelet plug
– Reversible and does not involve secretion
– ADP & 5-HT are principal mediators
– Heparin does not interfere with this process
– Aspirin & NSAIDS are both inhibitory (Aspirin causes irreversible blockade
14. Physiology Of Haemostasis cont…
• Release reaction
– Platelets degranulates releasing powerful mediators
– The Platelet plug becomes compacted to form an irreversible amorphous
plug.
– Mitigated by ADP, platelet factor 4, trace thrombin, in the presence of Ca2+,
Mg2+
– Products include: platelet factor 3 & 4, thromboglobulin, PDGF, ADP, 5-HT,
Ca2+
– Process is inhibited by cAMP
15. Physiology Of Haemostasis cont…
Coagulation/Fibrin Formation
• Aims to convert prothrombin into the proteolytic enzyme thrombin.
• Thrombin cleaves fibrinogen molecules to insoluble fibrin
• fibrin provides stability to the platelet plug.
• Involves two pathways:
– Intrinsic Pathways (factors VII, X, II)
– Extrinsic Pathways (factors XII, XI, IX, X and II)
17. Physiology Of Haemostasis cont.…
Fibrinolysis
• Aim is to maintain patency of blood vessels by lysis of fibrin deposits
• Initiated from start by circulating kinases, tissue activators, and
kallikrein.
• Dependent on Plasmin which lyses fibrin to produce fibrin
degradation end products
• Smaller products interfere with platelet aggregation while the larger
products incorporates into the clot resulting in unstable clots
18. Causes of excessive bleeding during or after
surgery
• Defects of hemostasis
• Mismatched blood transfusion
• Transfusion with plasma expanders especially dextran
• Shock
• Septicemia
• Liver disease
19. Surgical procedures associated with excessive bleeding
1. Prostatic surgery
2. Transplant surgery
3. Portacaval shunts
4. Extracorporeal circulation
20. Causes of bleeding during or after surgery
cont…
Defects of hemostasis
1. Defective Vasoconstriction
• Idiopathic Hemorrhagic Telengiectasia/ Osler Weber Rendu syndrome
• low perivascular pressure in muscular dystrophy, Ehlers-Danlos syndrome,
elderly, prolonged steroid therapy
21. Causes of bleeding during or after surgery
cont…
Defective Platelet Function
• Congenital:
• Bernard Soulier syndrome (GP 1b/IX/V receptor for vWF),
• Glanzman Thrombastenia (GP IIb/IIIA)
• Storage pool disease: Dense and α granules (occur with partial albinism in
Hermansky-Pudlak syndrome)
• Treatment: DDAVP(Desmopressin), platelet concentrate
22. Causes of bleeding during or after surgery
cont…
Acquired platelet disorders.
A. Quantitative Disorders:
1. Failure of production: (related to impairment in bone marrow function):
• Leukemia.
• Myeloproliferative disorders.
• B12 or folate deficiencies.
• Chemotherapy or radiation therapy.
• Acute alcohol intoxication
• Viral infections
23. Causes of bleeding during or after surgery
cont…
2. Decreased survival
• Immune-mediated
– Idiopathic thrombocytopenia (ITP)
– Heparin-induced thrombocytopenia
– Autoimmune disorders or B-cell malignancies
– Secondary thrombocytopenia.
• Disseminated intravascular coagulation (DIC)
• Related to platelet thrombi
– Thrombocytopenic purpura (TTP)
– Hemolytic uremic syndrome (HS)
24. Causes of bleeding during or after surgery
cont…
3. Sequestration.
• Portal hypertension.
• Sarcoid.
• Lymphoma.
• Gaucher’s Disease.
B. Qualitative Disorders
• Massive transfusion
• Therapeutic platelet inhibitors (aspirin, clopidogrel, prasugrel dipyridamole, GPIIb/IIIa
inhibitors)
• Disease states
• Myeloproliferative disorders
• Monoclonal gammopathies
• Liver disease, ureamia
25. Causes of bleeding during or after surgery
cont.…
Coagulation Factor Deficiencies
• Congenital
– Haemophilia A (Factor VIII deficiency) Von willibrands Disease (treatment:
desmopressin & vWF concentrate)
– Haemophilia B (Factor IX deficiency/Christmas disease)
– Haemophilia C (Factor XI deficiency) (treatment: FFP)
• Acquired
– Vit. K Deficiency (Factor II, VII, IX & X; III, VIII, XI, Protein C, fibrinogen)
– Ureamia
– Massive Blood Transfusion
– DIC
26. Methods of haemostasis
• Mechanical
• Direct pressure
• Gauze pack
• Suture and ligation
• staples
• Chemical/biological
• Local
• systemic
• Thermal
27. Methods of haemostasis cont…
Mechanical methods
• PRESSURE
• Immediate measure for capillary or venous
bleeding.
• Firm pressure should be applied over the
bleeding site using either fingers or gauze for at
least 5 minutes.
• This controls hemorrhages by counteracting
the hydrostatic pressure of the bleeding vessel.
• HAEMOSTAT
• Application of haemostat at the bleeding point
helps in direct occlusion of the bleeding vessel
28. Methods of haemostasis cont.…
SUTURES AND LIGATION
• Severed blood vessels may be tied
with ligatures. A ligature replaces
the hemostat as a permanent
method of effective hemostasis.
• For large pulsatile artery, a trans –
fixation suture to prevent slipping is
indicated.
• Non – resorbable sutures such as
silk and polyethylene are used as
they evoke less tissue reaction.
29. Methods of haemostasis cont.…
Chemical methods
Local Agents:
• Adrenaline
• Topical application of adrenaline brings about vasoconstriction of bleeding
capillaries.
• Available in ampoule, which is applied with the help of gauze.
• Concentration of 1 in 1000 is used for hemostasis over the oozing site.
• Thrombin
• Helps in converting fibrinogen into fibrous clot.
30. Methods of haemostasis cont…
• Surgicel
• Oxidized cellulose polymer obtained by dissolving pure alphacellulose in an
alkaline solution.
• Acts by forming acid products from partial dissolution that coagulates the
plasma proteins to form a black or brown sticky gelatinous clot.
• Applied surgicel resorbs from the site in 4 to 8 weeks.
• Disadvantage is that the surgicel clot is not formed by normal physiological
mechanism.
31. Methods of haemostasis cont.…
• Surgicel fibrillar:
• Modified surgicel or oxidized regenerated cellulose in
layers that can be adapted to irregular surfaces and
inaccessible areas.
• Complete resorption occurs in 2 weeks.
• Gelatine sponge or gelfoam or surgifoam:
• Formed from purified pork skin gelatin.
• Completely absorbable material.
• Has the capacity to absorb 45 times its weight in blood.
• Resorbs completely in 4 to 6 weeks.
32. Methods of haemostasis cont.…
• OXYCEL
• Oxidized cellulose polymer product.
• This absorbable hemostatic material is
manufactured by controlled oxidation of cellulose
using nitrous dioxide.
• Cellulosic acid present in it has affinity for
hemoglobin which leads to the formation of
artificial clot.
• Should be applied on the dry surface as the acid
formed during the wetting process inactivates the
thrombin.
• The platelets plug into its meshwork like surface
& helps in clot formation.
33. Methods of haemostasis cont.…
Microfibrillar collagen (avitene)
• Collagen derived from bovine skin cause
contact activation in addition to direct platelet
aggregation.
• Absorption time is 3 months.
• Fibrin glue
• Biological adhesive which contains thrombin,
fibrinogen, factor XIII, aprotinin.
• Thrombin converts fibrinogen to unstable fibrin
clot, factor XIII stabilizes the clot and aprotinin
prevents its degradation.
34. Methods of haemostasis cont.…
• Typtics & astringents
• Precipitates protein & arrests bleeding.
• Commonly used styptics & astringents are Monsel’s solution containing ferric
subsulfate & tannic acid.
• Thrombin & gelatin sponge are now widely used.
• Alginic acid
• Placed over the bleeding sites, a protective film is formed over the bleeding site, this
film compresses the capillaries & stabilizes the blood clot.
• Natural collagen sponge
• White sponge material, fully absorbable. It stimulates the platelet aggregation
thereby enhancing hemostasis.
• Activates coagulation factors XI & XIII.
• Preferred in patients who are susceptible for hemorrhage after dental surgical
procedures.
35. Methods of haemostasis cont.…
• Fibrin sponge
• Obtained from bovine material.
• Chemically treated to avoid allergic reactions.
• Applied on the bleeding site especially in post extraction socket.
• Fully absorbed by the tissues within 4-6 weeks.
• OSTENE (a new water soluble bone hemostatic agent)
• New bone hemostatic agent, made of water-soluble alkylene oxide copolymers.
• Showed no incidence of adverse response in the cortical defect site, medullary cavity
or the surrounding tissue.
36. Methods of haemostasis cont.…
• Bone wax
• Sterilized, non – absorbable mix of waxes.
• Consists of seven parts by weight of wax (white bees wax, paraffin wax & an
isopropyl ester of palmitic acid), two parts of olive oil and one part of phenol.
• Indicated in cases of bleeding from the bone or from chipped edges of bone.
• Bone wax is softened with the fingers to desired consistency & then applied
over the bleeding site.
• Its hemostatic mechanism is through mechanical obstruction of the osseous
cavity containing the bleeding vessels.
37. Methods of haemostasis cont.…
Systemic Agents:
• Whole Blood:
• Fresh whole blood refers to blood that is administered within 24 hours of its
donation.
• Whole blood transfusion indicated when there is excessive blood loss.
• Contains all factors for coagulation.
• Must be checked for HIV, hepatitis B, C viruses.
• Platelet Rich Plasma:
• Platelets can be collected from donated whole blood.
• Platelet concentrates are viable for 3 days when stored at room temperature.
• Must be infused quickly via short i.v. transfusion set.
• One unit raises platelet count by approx 7,000 to 10,000 cells per cu mm.
38. Methods of haemostasis cont.…
• Fresh Frozen Plasma:
• Unit of fresh frozen plasma is collected from one donor and contains all
coagulation factors.
• Stored at -30°C, should be infused within 2 hours once defrosted.
• Cryoprecipitate:
• Stored at -30°C.
• Each bag is derived from single donor and is not treated to inactivate viruses.
• Associated with a substantial risk of viral transmission.
39. Methods of haemostasis cont.…
Thermal agents
• Heat achieves hemostasis by
denaturation of proteins.
• Cautery:
• Heat is transmitted from instrument by
conduction directly to the tissues.
• Electro – cautery has replaced direct
heat application.
40. Methods of haemostasis cont.…
• Electrocautery:
• Most widely used.
• Electrocautery can be applied directly to bleeding point.
• Cautery point is touched to the hemostat, causing sealing of vessel through
action of heat.
• Causes tissue destruction producing burning smell and smoke during
application.
• Effective and convenient way of controlling hemorrhage.
41. Methods of haemostasis cont.…
• Advantages of electrocautery:
• Permits any degree of hemorrhage
control.
• Provides clear and improved view.
• Increases efficiency.
• Reduces chair side time.
• Gives pressure – less cutting.
42. Methods of haemostasis cont.…
• Cryosurgery:
• Extreme cooling has been used for hemostasis.
• Temperature ranging from -20°C to -180°C are used.
• Tissues, capillaries, small arterioles and venules
undergo cryogenic necrosis.
• Caused by dehydration and denaturation of lipid
molecules.
• Specially used to treat superficial hemangiomas.
• Lasers:
• Lasers usually result in bloodless surgery.
• Effectively coagulate the small blood vessels during
cutting of tissues.
43. Management
Pre Op Evaluation
• History
– Hx of abnormal bleeding, prolonged bleeding, easy bruising, mucosal bleeds,
menorrhagia
– Hx of coagulation disorder in relatives
– Hx of use of anticoagulant.
– Hx of chronic diseases such as CKD, CVDs, CLD, HTN
– Hx of use of drugs e.g. cytotoxic, anticoagulants.
Aspirin 7-10days, clopidogrel 7days, ticlopidine 10days, OCPs 6wks, monoamine
oxidase 2-3wks, warfarin 5days in patients with INR between 2-3, 6 days for INR 3-4.5,
LMWH 24 hours before surgery
• Examination
– General examination (anemia, jaundice, asterixis, anasarca)
– Skin: ecchymosis, stigmata of cld
– Abd: Hepatomegaly, splenomegaly, ballotable kidneys
– Bed side bleeding time (1-9min, up to 13min in children)
44. Management cont.…
• Investigations
– General: CBC, LFT, E/U/Cr, Abd USS
– Specific -tests of hemostasis
• CT (8-15min)
• PT (VII, X, II) (9.6-11.8sec)
• PTT (XII, XI, IX, X & II) (20-36sec)
• INR, Fx assays, fibrinogen level, Clot elastography and elastometry,
50. Hemostasis in trauma
• Pre hospital use of tranexamic acid
• Prothrombin complex concentrate
• Damage control resuscitation
– Prompt mechanical or surgical hemorrhage control
– Permissive hypotension
– Minimalistic crystalloid/ synthetic colloid based resuscitation
– Early use of blood products in the ration of 1:1:1 of PRBC:FFP:Platelets
51. Conclusion
• Understanding the concept of haemostasis is important in achieving a
good surgical outcome
• It is the responsibility of the surgeon to preempt surgically important
haemorrhage, employ multiple modalities to prevent it, and arrest it
when it does occur.
• All bleeding (eventually) stops